News
Altimmune, Inc.'s Pemvidutide shows promise in MASH treatment with liver improvements and safety, despite market overreaction. Click for my ALT stock update.
9h
Zacks Investment Research on MSNCan LLY's Next-Generation Obesity Pipeline Fuel Further Growth?Eli Lilly LLY has experienced significant growth in the past few years, particularly driven by the success of its popular ...
Phase 3 REDEFINE 1 trial found that treatment with CagriSema led to a 22.7% weight loss at 68 weeks among patients who adhered to the treatment, compared ...
Top Alternatives to Ozempic That Are EffectiveReviewed by Dr. Craig Primack, MD, FACP, FAAP, FOMAOzempic is a medication ...
20d
Zacks Investment Research on MSNIs Novo Nordisk's Next Generation Obesity Pipeline a Game Changer?Novo Nordisk NVO has seen strong momentum in recent years, driven by the commercial success of its blockbuster semaglutide products, Wegovy (obesity) and Ozempic (diabetes). Building upon this success ...
Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, known as Ozempic and Wegovy, according to new research.
Over the following year it yielded $4.9bn in revenue, more than half Wegovy’s $8.2bn. On May 7th Novo cut its sales forecast for 2025, citing “lower-than-planned” growth in weight-loss drugs.
VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes SAN DIEGO, June 25, 2025 /PRNewswire/ -- Viking ...
In March, Novo Nordisk launched NovoCare Pharmacy to provide direct-to-patient, convenient home shipments of all Wegovy dose strengths at a reduced cost of $499 per month for self-paying patients.
The patients started on low doses and increased gradually, reaching the full Wegovy dose over 72 weeks. Boxes of Wegovy made by Novo Nordisk are seen at a pharmacy in London, March 8, 2024.
Novo Nordisk NVO announced an update to the savings offer for its popular obesity injection, Wegovy (semaglutide).This update allows cash-paying patients or those with commercial insurance, which ...
Novo Nordisk is cutting the cost of its blockbuster weight-loss drug Wegovy in half for U.S. patients paying cash through its direct-to-patient online pharmacy, as competition in the highly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results